David Redfern appointed as new chairman of ViiV Healthcare

David Redfern appointed as new chairman of ViiV Healthcare

GlaxoSmithKline (GSK), ViiV Healthcare, and Pfizer announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1st April 2011, following the retirement of Julian Heslop.  David will continue to serve as Chief Strategy Officer at GSK, which owns a majority share in ViiV Healthcare.

GlaxoSmithKline (GSK), ViiV Healthcare, and Pfizer announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1st April 2011, following the retirement of Julian Heslop.  David will continue to serve as Chief Strategy Officer at GSK, which owns a majority share in ViiV Healthcare. 

“David played a significant role in the creation of ViiV Healthcare and brings his extensive depth of knowledge of the pharmaceutical industry to the Board” said Julian Heslop, current Chairman of the Board for ViiV Healthcare. 

David was appointed GSK’s Chief Strategy Officer in May 2008 and is responsible for proactive exploration of new business opportunities and strategic planning.  Previously, he served as Senior Vice President, Northern Europe with responsibility for managing GSK's pharmaceutical business, and prior to that was the Senior Vice President and Chief Financial Officer of Pharma Europe.  David also had overall responsibility for the European HIV business from 2006 to 2008.

“I am looking forward to the renewed challenge as chair of the board for ViiV Healthcare and supporting this highly focused HIV company as it grows over the coming years.  This will be an exciting time in the delivery of ViiV Healthcare and I am pleased to be part of its future success.”  commented David Redfern on his appointment.

GlaxoSmithKline—one of the world’s leading research-based pharmaceutical and healthcare companies—is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com

ViiV Healthcare—is a global specialist HIV company established in November 2009 by GlaxoSmithKline (NYSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV. Our aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline and commitment, please visit www.viivhealthcare.com.

Pfizer Inc: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish